WASHINGTON, Sept. 28 (UPI) -- The U.S. Food and Drug Administration has approved Folotyn as the first treatment for a form of cancer known as peripheral T-cell lymphoma.
Folotyn (pralatrexate) was approved under the FDA's accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs, officials said. It is approved for patients who have relapsed, or have not responded well to other forms of chemotherapy....
FDA Advisory Committee Recommends Gloucester Pharmaceuticals` Romidepsin for Approval for Cutaneous T-cell Lymphoma
CAMBRIDGE, Mass.--(Business Wire)--
Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). CTCL is a type of non-Hodgkin's lymphoma, which...
Researchers affiliated with the European Working Party of the European Group for Blood and Marrow Transplantation have reported that allogeneic stem cell transplantation results in long-term disease-free survival in approximately 50% of patients with angioimmunoblastic T-cell lymphoma (AITL). The details of this study appeared in an early online publication on July 20, 2009 in the Journal of Clinical Oncology.[1]
T-cell lymphomas are a relatively uncommon form of non-Hodgkin’s lymphoma...
ScienceDaily (Sep. 2, 2008) — The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin’s lymphoma.
The study is based on research from VCU Massey Cancer Center as well as other centers suggesting that combining two novel, recently approved drugs that have shown effectiveness in certain blood cancers may be active in patients with diffuse large B-cell lymphoma, or...
